UnitedHealth drops Nexium
This article was originally published in The Tan Sheet
Executive Summary
Astra-Zeneca's proton pump inhibitor Nexium (esomeprazole) was dropped from some UnitedHealth Group plans Sept. 1 and will be let go from others later this year, the firm says. The cost-sensitive measure reflects the lower-cost availability of Nexium predecessor Prilosec OTC (omeprazole), which AZ co-markets with Procter & Gamble. AZ is disappointed with the decision, saying it is not good for patients and overrides the better judgment of healthcare professionals, according to a spokesperson. The firm is not revising Nexium revenue projections. In recent years, other payors have chosen to remove Nexium and other PPIs from formularies, or to provide coverage for Prilosec OTC (1"The Tan Sheet" May 16, 2005, p. 11)...
You may also be interested in...
OTC Impact: DoD Nexium Formulary Move Could Preface Future Cost-Cutting
The Defense Department's decision to cease pharmacy benefit coverage of AstraZeneca's Nexium could pave the way for similar cost-cutting measures in other federal employee health plans
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.